VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CLLS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CLLSCellectis S.A.
$1.03$103M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksCLLSCash Flow

Cellectis S.A. (CLLS) Cash Flow Statement

19Y historyFree accessUpdated daily

Liquidity is under severe pressure, with cash and equivalents falling from a peak of $159.1 million in 2024Q3 to $35.0 million in 2026Q1, highlighting a persistent inability to achieve self-sustaining free cash flow.

Income StatementBalance SheetCash FlowRatios

CLLS Cash Flow Statement

Annual statement

CLLS Cash Flow Statement

Cellectis S.A. (CLLS) cash flow statement — 19-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07
Cash from Operations-41.89M-40.14M22.1M-24.75M-87.44M-104.56M-80.26M-69.14M-68.14M-52.33M-31.09M3.54M50.74M-25.63M-26.11M-13.19M-21.1M-7.05M1.78M-5.62M
Operating CF Margin %--55.02%53.25%-3277.62%-456.13%-344.57%-157.2%-455.18%-535.21%-207.75%-73%6.43%192.93%-112.33%-93.87%-63.64%-100.58%-40.7%12.05%-137.08%
Operating CF Growth %-22140.03%-281.59%189.32%71.7%16.37%-30.28%-16.08%-1.47%-30.21%-68.32%-978.69%-93.03%297.97%1.84%-97.93%37.48%-199.35%-496.22%131.64%-
Net Income-65.35M-67.8M-36.7M-116.83M-98.69M-96.75M-53.58M-115.21M-88.33M-103.68M-63.92M-22.27M2.25M-85.77M-29.45M-30.9M-10.72M-5.52M185.15K-4.36M
Depreciation & Amortization19.08M20.06M19.85M18.52M18.43M14.16M7.83M6.88M2.38M3.37M2.21M1.91M1.67M45.93M2.42M01.58M368.21K400.92K852.93K
Stock-Based Compensation2.29M005.23M6.04M11.49M10.03M26.88M37.22M50.42M55.71M32.91M666.37K634.86K254.47K0578.53K0281.2K351.38K
Deferred Taxes26K00371K87K0006.46M4.32M1.32M0-567.88K4.68M00-4.04M0-1.23M-2.32M
Other Non-Cash Items33.04K49.33M-14.62M71.95M-7.6M-21.16M-27.22M661K-16.76M11.04M-1.51M-7.49M-8.99M1.1M10.01M12.54M191.51K0-8.35K-481.14K
Working Capital Changes2.05M-41.72M53.57M-3.99M-5.72M-12.3M-17.32M11.65M-9.1M-17.79M-24.9M-1.52M55.72M8.57M-6.67M5.16M-8.69M-1.9M2.15M333.88K
Change in Receivables4.21M-4.44M-6.72M2.25M-8.99M-12.44M-3.23M4.68M-3.7M-549K-947.58K1.25M-8.48M4.08M-3.53M00000
Change in Inventory00000215K100K-2.63M-37K-109K47.33K-25.15K117.95K462.59K-80.43K00000
Change in Payables2.47M-3.27M2.05M-6.3M3.25M177K5.69M9.63M9.37M-335K-4.17M2.92M-819.59K0000000
Cash from Investing31.66M-29.58M-102.63M-15.51M-2.76M7.28M-54.34M-35.87M35.62M1.78M-50.5M-7.61M-1.65M-2.08M-6.1M-29.41M-5.69M316.64K-1.12M316.39K
Capital Expenditures-2.19M-3.54M-3.84M-1.07M-2.43M-18.54M-44.08M-12.91M-4.89M-2.66M-13.34M-4.25M-430.47K-1.91M-5.49M-4.25M-6.66M-713.51K-790.71K-147.26K
CapEx % of Revenue3.87%4.86%9.24%142.12%12.68%61.11%86.33%85.01%38.38%10.54%31.32%7.73%1.64%8.39%19.72%20.49%31.73%4.12%5.35%3.59%
Acquisitions000000001.26M7.16M-298.68K-3.12M614.09K0000000
Investments--------------------
Other Investing-2.26M00-14.44M-456K10.96M-13.15M369K1.26M7.16M321.82K14.21K-1.83M-169.85K-611K-25.17M969.54K1.03M0463.64K
Cash from Financing-16.37M-16.2M89.8M82.86M1.15M47.52M27.32M-3.86M236.49M41.27M460.64K217.35M70.41M7.5M4.93M66.39M-1.18M30.91M4.05M34.79M
Debt Issued (Net)-10.24M-5.4M18.17M24.56M-6.6M-10.64M19.43M-3.39M-127K-41K-91K-625K-1.37M-509.81K372.95K66.9M-1.31M-1.5M-218.56K0
Equity Issued (Net)248.25K44.14K82.68M67.94M-569K44.64M9.21M0228.85M41.31M576K221.22M71.67M7.7M3.44M2.21M127.68K31.94M4.26M0
Dividends Paid00000000000000000000
Share Repurchases0000-569K00-469K00-137K00-318.63K-32.11K-20.86K0000
Other Financing-6.38M-10.85M-11.04M-9.63M8.32M13.53M-1.32M-469K7.77M00-1K-209.05K-20.45K970.61K-2.72M965.35K-45.64K034.79M
Net Change in Cash-26.11M-79.67M6.54M43.49M-92.42M-55.51M-99.37M-110.98M195.12M1.81M-76.5M220.73M127.42M-19.68M-27.21M23.77M-27.97M24.17M4.7M29.49M
Free Cash Flow-44.06M-42.5M19.52M-25.82M-89.89M-123.12M-124.68M-82.1M-73.02M-54.98M-44.42M-715.02K50.31M-27.54M-31.6M-17.44M-27.76M-7.76M988.39K-5.77M
FCF Margin %-77.87%-58.27%47.04%-3419.74%-468.86%-405.71%-244.21%-540.49%-573.58%-218.29%-104.32%-1.3%191.29%-120.72%-113.59%-84.13%-132.3%-44.82%6.69%-140.67%
FCF Growth %-20.41%-317.7%175.62%71.28%26.99%1.26%-51.87%-12.43%-32.81%-23.77%-6113.1%-101.42%282.65%12.83%-81.18%37.17%-257.58%-885.38%117.13%-
FCF per Share-0.44-0.420.22-0.45-1.97-2.90-2.93-1.93-1.79-1.54-1.24-0.021.92-1.33-1.58-1.23-1.96-0.550.07-0.41
FCF Conversion (FCF/Net Income)0.67x0.59x-0.60x0.24x0.82x0.92x0.99x0.68x0.87x0.53x0.49x-0.16x2086.27x0.30x0.89x0.43x1.97x1.28x9.61x1.29x
Interest Paid00000000000000000000
Taxes Paid00000000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Clinical Milestone Funding Dependency

Earnings Quality Masked by Milestones

As reported in recent financial filings, the relationship between net income and operating cash flow is highly erratic, with OCF/NI ratios fluctuating wildly from -4.13 in 2024Q1 to 0.87 in 2026Q1, reflecting the company's reliance on non-recurring milestone payments rather than sustainable operational cash generation.

The extreme volatility in the conversion of net income to cash suggests that reported earnings are heavily influenced by accounting recognition of partnership milestones rather than core business performance. Investors should interpret these figures with caution, as the lack of a consistent positive correlation between income and cash flow indicates that the company's earnings quality remains fundamentally strained.

Persistent Free Cash Flow Deficits

Based on the provided cash flow data, Cellectis exhibits a persistent free cash flow deficit, with the company recording negative FCF in nine of the last ten quarters, highlighting a structural inability to self-fund operations through its current therapeutic development pipeline and partnership-driven revenue model.

The sporadic positive FCF quarters appear to be outliers driven by large, one-time working capital inflows rather than organic operational improvements. This trajectory suggests that the company remains in a capital-intensive phase where cash burn is the primary operational reality, necessitating ongoing external financing to maintain its clinical programs.

Working Capital Volatility Drives Liquidity

According to historical cash flow statements, working capital changes are the primary driver of short-term liquidity, with massive swings such as the $61.0 million inflow in 2024Q2, which suggests that the company's cash position is highly sensitive to the timing of partner payments and milestone settlements.

These large, lumpy working capital movements indicate that the company lacks a predictable cash conversion cycle. The reliance on these inflows to offset operating losses implies that any delay in milestone achievement could lead to immediate liquidity pressure, warranting close monitoring of accounts receivable and deferred revenue balances.

Capital Intensity Remains Relatively Low

As indicated by the provided data, Cellectis maintains a relatively low capital intensity, with CapEx/Revenue ratios generally remaining in the low single digits, suggesting that the company's primary cash drain is operational R&D rather than heavy investment in physical manufacturing infrastructure or equipment.

While the company has invested in its own manufacturing facilities, the relatively modest CapEx figures suggest that the bulk of its capital is consumed by clinical trial costs and personnel rather than asset-heavy expansion. This implies that the company's financial risk is tied more to the success of its clinical programs than to the maintenance of its physical asset base.

CLLS — Frequently Asked Questions

Quick answers to the most common questions about buying CLLS stock.

How much cash does Cellectis S.A. (CLLS) generate from operations?

Cellectis S.A. (CLLS) generated $-40.1M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Cellectis S.A.'s free cash flow?

Cellectis S.A. (CLLS) reported negative free cash flow of $42.5M in 2025, indicating capital requirements exceeded cash from operations.

What is Cellectis S.A.'s capital expenditure (CapEx)?

Cellectis S.A. (CLLS) spent $3.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.